These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 12194070)

  • 1. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
    Newman WD; Tocher K; Acheson JF
    Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.
    Best JL; Acheson JF
    Eye (Lond); 2005 Jan; 19(1):41-4. PubMed ID: 15094729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.
    Kinirons P; Cavalleri GL; O'Rourke D; Doherty CP; Reid I; Logan P; Liggan B; Delanty N
    Epilepsia; 2006 Feb; 47(2):311-7. PubMed ID: 16499754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods].
    Riise P; Fledelius HC; Rogvi-Hansen Bà
    Ugeskr Laeger; 2003 Mar; 165(10):1034-8. PubMed ID: 12645411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
    Conway M; Cubbidge RP; Hosking SL
    Epilepsia; 2008 Jan; 49(1):108-16. PubMed ID: 18184224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
    Daneshvar H; Racette L; Coupland SG; Kertes PJ; Guberman A; Zackon D
    Ophthalmology; 1999 Sep; 106(9):1792-8. PubMed ID: 10485552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Visual field changes secondary to vigabatrin treatment].
    Mauri-Llerda JA; Iñiguez C; Tejero-Juste C; Santos-Lasaosa S; Escalza-Cortina I; Ascaso-Puyuelo J; Abad-Alegría F; Morales-Asín F
    Rev Neurol; 2000 Dec 16-31; 31(12):1104-8. PubMed ID: 11205539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
    Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
    J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
    Lawthom C; Smith PE; Wild JM
    Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vigabatrin and epilepsy: lessons learned.
    Wild JM; Ahn HS; Baulac M; Bursztyn J; Chiron C; Gandolfo E; Safran AB; Schiefer U; Perucca E
    Epilepsia; 2007 Jul; 48(7):1318-27. PubMed ID: 17635558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
    Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
    Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binasal visual field defects are not specific to vigabatrin.
    Gonzalez P; Sills GJ; Parks S; Kelly K; Stephen LJ; Keating D; Dutton GN; Brodie MJ
    Epilepsy Behav; 2009 Nov; 16(3):521-6. PubMed ID: 19815465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The function of eye and vision system in children and youth treated with vigabatrin--our own experiences].
    Pojda-Wilczek D; Emich-Widera E; Herba E; Pojda SM; Marszał E
    Klin Oczna; 2005; 107(10-12):654-7. PubMed ID: 16619812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vigabatrin-associated visual field defects in children.
    Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vigabatrin-attributable visual field defects in patients with intractable partial epilepsy.
    Tseng YL; Lan MY; Lai SL; Huang FC; Tsai JJ
    Acta Neurol Taiwan; 2006 Dec; 15(4):244-50. PubMed ID: 17214087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
    Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
    Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study.
    Schmitz B; Schmidt T; Jokiel B; Pfeiffer S; Tiel-Wilck K; Rüther K
    J Neurol; 2002 Apr; 249(4):469-75. PubMed ID: 11967655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
    Sergott RC; Bittman RM; Christen EM; Sagar SM
    Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss--could scanning laser polarimetry aid diagnosis?
    Durnian JM; Clearkin LG
    Eye (Lond); 2008 Apr; 22(4):559-63. PubMed ID: 17401319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
    Werth R; Schädler G
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):3028-35. PubMed ID: 16799049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.